$CYTOF News

Altamira Therapeutics Announces Publication Highlighting Potential of RNA Nanoparticles for Disease-Modifying Treatment of Osteoarthritis

Altamira Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Altamira Therapeutics Announces Release Date for 2025 Annual Report and Financial Statements

Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Bentrio Nasal Spray

Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit

Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China

Altamira Therapeutics Announces Certification of Bentrio Nasal Spray under Medical Device Regulation

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules

Altamira Therapeutics Provides Business Update and First Half 2025 Financial Results

Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025

Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Intranasal Betahistine

Altamira Therapeutics Announces Collaboration on Circular RNA Delivery

Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results

Altamira Therapeutics Ltd. (CYTOF) Q4 2024 Earnings Call Transcript

Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025

Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent

Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets